Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM5ST9Z)

• Drug Name: Zolbetuximab Drug Info
• Synonyms: IMAB362

Indication

Disease Entry	ICD 11	Status	REF
Esophagogastric junction neoplasm	2B71	Phase 3	[1]
Gastric adenocarcinoma	2B72	Phase 3	[1]
Pancreatic cancer	2C10	Phase 2	[2]

• Cross-matching ID: TTD Drug ID: DM5ST9Z

Molecule-Related Drug Atlas

Drug(s) Targeting Claudin-18 (CLDN18)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Claudiximab	DMPQR1D	Gastric adenocarcinoma	2B72	Phase 3	[4]
CT-041	DM5XX06	Gastric cancer	2B72	Phase 1/2	[5]
RC118	DMU25QT	Aggressive cancer	2A00-2F9Z	Phase 1/2	[6]
AMG 910	DMCG7XL	Esophagogastric junction neoplasm	2B71	Phase 1	[7]
TST001	DMZ9EMO	Solid tumour/cancer	2A00-2F9Z	Phase 1	[8]
SKB315	DMI0JT4	Aggressive cancer	2A00-2F9Z	Phase 1	[9]
ASP2138	DM96QLF	Stomach cancer	2B72	Phase 1	[10]
CAR-CLD18 T cell	DM6ZHTV	Adenocarcinoma	2D40	Clinical trial	[11]
BNT212	DM27NTT	Aggressive cancer	2A00-2F9Z	Preclinical	[12]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Claudin-18 (CLDN18)	TT6PKBX	CLD18_HUMAN	Not Available	[3]

References

• [1] ClinicalTrials.gov (NCT03504397) A Phase 3 Efficacy, Safety and Tolerability Study of Zolbetuximab (Experimental Drug) Plus mFOLFOX6 Chemotherapy Compared to Placebo Plus mFOLFOX6 as Treatment for Gastric and Gastroesophageal Junction (GEJ) Cancer (Spotlight). U.S. National Institutes of Health.
• [2] ClinicalTrials.gov (NCT03816163) A Study to Assess the Antitumor Activity and Safety of IMAB362 in Combination With Nab-Paclitaxel and Gemcitabine (Nab-P + GEM) as First Line Treatment in Subjects With Claudin 18.2 (CLDN18.2) Positive, Metastatic Pancreatic Adenocarcinoma. U.S. National Institutes of Health.
• [3] FAST: a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma. Ann Oncol. 2021 May;32(5):609-619.
• [4] Claudin 18.2 is a target for IMAB362 antibody in pancreatic neoplasms. Int J Cancer. 2014 Feb 1;134(3):731-9.
• [5] Clinical pipeline report, company report or official report of CARSGEN
• [6] ClinicalTrials.gov (NCT05205850) An Open, Multi-center Phase I/IIa Clinical Study of RC118 for Injection in Patients With Locally Advanced Unresectable or Metastatic Malignant Solid Tumors With Positive Expression of Claudin 18.2. U.S.National Institutes of Health.
• [7] Clinical pipeline report, company report or official report of Amgen.
• [8] Clinical pipeline report, company report or official report of Transcenta.
• [9] Clinical pipeline report, company report or official report of Klus Pharma
• [10] ClinicalTrials.gov (NCT05365581) A Phase 1/1b Study of ASP2138 in Participants With Metastatic or Locally Advanced Unresectable Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma or Metastatic Pancreatic Adenocarcinoma Whose Tumors Have Claudin (CLDN) 18.2 Expression. U.S.National Institutes of Health.
• [11] ClinicalTrials.gov (NCT03302403) Clinical Study of Redirected Autologous T Cells With a Chimeric Antigen Receptor in Patients With Malignant Tumors
• [12] Clinical pipeline report, company report or official report of Biontech